| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 861 | 836 | 868 | 987 |
| Cost of product revenues | 49 | 46 | 44 | 68 |
| Research and development | 14,027 | 13,853 | 13,482 | 11,595 |
| Selling, general and administrative | 7,098 | 6,264 | 6,263 | 5,666 |
| Total expenses | 21,174 | 20,163 | 19,789 | 17,329 |
| Loss from operations | -20,313 | -19,327 | -18,921 | -16,342 |
| Interest (expense) income, net | -515 | -36 | 166 | 916 |
| Total other (expense) income | -515 | -36 | 166 | 916 |
| Net loss | -20,828 | -19,363 | -18,755 | -15,426 |
| Unrealized gain (loss) on marketable securities | 29 | -21 | -15 | 121 |
| Comprehensive loss | -20,799 | -19,384 | -18,770 | -15,305 |
| Earnings per share, basic | -0.4 | -0.5 | -0.49 | -0.41 |
| Earnings per share, diluted | -0.4 | -0.5 | -0.49 | -0.41 |
| Weighted average number of shares outstanding, basic | 52,186,503 | 38,392,716 | 38,235,409 | 37,621,495 |
| Weighted average number of shares outstanding, diluted | 52,186,503 | 38,392,716 | 38,235,409 | 37,621,495 |
Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. (OBIO)